Albert David Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Albert David Ltd is ₹ 685 as of 04 May 09:16 . The P/E Ratio of Albert David Ltd is 0 as of December 2023 .The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 . The Market Cap of Albert David Ltd is ₹ 0 crore as of December 2023 .The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 . The Revenue of Albert David Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Albert David Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Albert David Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The dividend payout of Albert David Ltd changed from 15.47 % to 16.6 % over 5 quarters. This represents a CAGR of 5.80% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% .

About Albert David Ltd

Albert David Limited (ADL), a Unit of Kothari Group, was incorporated in 1938 at Calcutta.
The Company belongs to a renowned industrial house of Kolkata, the 'Kothari Group'.
The Company's principal business is manufacturing and trading of Pharmaceutical Formulations, Infusion Solutions, Herbal Dosage Forms and Bulk Drugs by way of domestic sale or export.
Apart from these, it manufactures disposable syringes and needles and a wide range of bulk drugs.
It is recognised as a large IV fluid manufacturer, both in glass and polyethylene containers. ADL has entered into a technical collaboration with Morishita Pharmaceuticals, Japan, a subsidiary of Ajinomoto -- the world leader in amino acids -- to manufacture amino acid infusions, for which it came out with a rights issue in Aug.'87.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Albert David Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Albert David Ltd or Sanofi India Ltd?

Market cap of Albert David Ltd is 411 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Albert David Ltd and Sanofi India Ltd?

The stock performance of Albert David Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Albert David Ltd and Sanofi India Ltd?

As of May 4, 2026, the Albert David Ltd stock price is INR ₹720.05. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Albert David Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Albert David Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.